Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe
The first patient was enrolled at Mount Sinai Hospital in New York by Dr. Samin Sharma, Director of Interventional Cardiology [KG1], marking a crucial step in advancing treatment options for patients with small-vessel coronary artery disease.
'Today marks a great feat for us and for the MAGICAL-SV trial,' said Dr. Samin Sharma. 'My team at Mount Sinai is privileged to be the first to begin this study. This is a proud moment for all of us, especially knowing what the trial signifies and aims to achieve by evaluating MagicTouchas a potential alternative for treating small vessels in the U.S.'
This initial U.S. enrollment follows the FDA's IDE approval of Concept Medical's MagicTouch SCB and boosts the company's broader coronary clinical program. Concept Medical is now actively enrolling in three IDE trials concurrently in the U.S., spanning across coronary and peripheral interventions and underscoring its commitment to bringing innovative therapies to patients worldwide.
MAGICAL-SV is a prospective, multicenter, single-blind randomized trial (2:1 randomization) comparing Concept Medical's MagicTouch sirolimus-coated balloon to drug-eluting stents (Everolimus eluting stents [EES] or Zotarolimus eluting stents [ZES]) for the treatment of small coronary artery lesions. Randomization is stratified by study site and presence of medically-treated diabetes mellitus status. The trial will enroll 1,605 patients across the U.S. and Europe, to evaluate the primary endpoint of target lesion failure (TLF) at 12 months.
The MAGICAL-SV trial is led by an international team of renowned cardiologists, Dr. Martin B. Leon (USA) serves as Study Chair, with principal investigators (PI) Dr. Azeem Latib (USA), Dr. Ajay Kirtane (USA), and Prof. Antonio Colombo (Europe).
Dr. Azeem Latib, a U.S. PI for MAGICAL-SV, noted, 'The first U.S. patient enrollment in the MAGICAL-SV study marks an exciting step forward in building robust evidence for sirolimus-coated balloon technology in the treatment of small-vessel coronary disease. As we explore metal-free PCI strategies, this study brings renewed hope for safer, more effective options for our patients.'
Prof. Antonio Colombo, who leads the European arm of the study, added, 'Starting small and going big! MAGICAL-SV represents an important step in building evidence for sirolimus-coated balloons.'
This milestone embodies a 'leave nothing behind' philosophy in coronary interventions, treating arterial blockages without permanent implants and addressing the limitations of metallic stents in small vessels. Dr. Martin B. Leon, the Study Chair, emphasized the significance of evaluating a no-stent strategy through this trial: 'The initiation of the MAGICAL-SV trial marks an important step in evaluating sirolimus-coated balloon therapy for small coronary vessels. By addressing key limitations of stenting in this complex anatomy, the study aims to generate strong comparative data versus DES. The results could inform future treatment strategies in the U.S. and Europe, offering clinicians a potential alternative for managing small-vessel disease.'
With this pioneering trial, MAGICAL-SV is expected to yield compelling clinical evidence in support of sirolimus-coated balloon therapy. The outcomes will also support Concept Medical's Pre-Market Approval (PMA) application for the MagicTouch SCB in small-vessel indication, potentially transforming the standard of care in coronary artery disease.
Dr. Manish Doshi, Founder and Managing Director of Concept Medical, said, 'At Concept Medical, our unwavering commitment to innovation and patient care drives us to push the boundaries of what is possible in vascular interventions. The initiation of MAGICAL-SV reinforces our dedication to delivering next-generation, evidence-based solutions to clinicians and patients across the globe. Our ultimate goal is to transform the current standard of care and provide better outcomes and quality of life for patients affected by CAD.'
About MagicTouch SCB
MagicTouch SCB is Concept Medical's sirolimus-coated balloon platform, developed with proprietary Nanoluté technology to deliver sub-micron particles of sirolimus in a biocompatible carrier for deep arterial wall penetration. The device has received CE Mark approval in Europe and a Breakthrough Device designation from the U.S. FDA for small coronary vessels and in-stent restenosis.
About Concept Medical
Concept Medical Inc., headquartered in Tampa, Florida, is a global leader in cutting-edge drug-delivery technologies for cardiovascular interventions. The company is dedicated to improving patient care through research and development of novel drug-delivery platforms engineered to precisely deliver therapeutic agents to diseased vascular tissue. Concept Medical's MagicTouch family of sirolimus-coated balloons is the world's first and most widely used SCB technology, recognized for its versatility, safety and efficacy in treating coronary and peripheral artery disease. The revolutionary MagicTouch and Abluminus product lines have treated over one million patients worldwide, setting a new benchmark in vascular therapy.
For media inquiries, please contact: pr@conceptmedical.com
(Disclaimer: The above press release comes to you under an arrangement with PNN and PTI takes no editorial responsibility for the same.). PTI
This is an auto-published feed from PTI with no editorial input from The Wire.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
6 hours ago
- Hindustan Times
State issues new mid-day meal guidelines
In a significant step to enhance food safety in schools, the Maharashtra government has issued a comprehensive Standard Operating Procedure (SOP) under the Pradhan Mantri Poshan Shakti Nirman Yojana. The SOPs aim to prevent incidents of food poisoning and lay out strict responsibilities for school authorities, teachers, cooks, education officers, and food safety departments to ensure that meals served to students from Classes 1 to 8 are hygienic, nutritious, and safe. A key provision mandates that headmasters or designated teachers must taste the cooked meal at least 30 minutes before it is served to students. (REPRESENTATIVE PHOTO) According to the new guidelines, school management committees (SMCs) must verify the quality and expiry dates of food supplies, including rice, oil, and spices, before accepting them from vendors. Grains must be stored above ground level in clean, pest-free environments. Drinking water tanks are to be cleaned regularly, and proper handwashing facilities with soap must be made available to all students. Meals must be prepared only in designated kitchen areas. A key provision mandates that headmasters or designated teachers must taste the cooked meal at least 30 minutes before it is served to students. If available, parents may also participate in this process. Feedback regarding the meal's taste, smell, and appearance must be recorded in an official register. Food is to be served only if it meets acceptable standards. Cooks and helpers involved in meal preparation are required to undergo medical check-ups every six months. They must wear clean clothing, keep their nails trimmed, and wash their hands with soap before cooking. Staff are also instructed to follow the 'first in, first out' method to ensure proper grain rotation and prevent mixing old and new supplies. The Food and Drug Administration (FDA) will oversee the implementation of food safety measures, conduct training sessions for school staff on hygienic food handling practices, and periodically test food and water samples from schools. In the event of a food poisoning incident, the SOP outlines a clear emergency response protocol. Affected students must be isolated and taken to the nearest healthcare facility without delay.
Economic Times
12 hours ago
- Economic Times
Kratom addiction alarm grows in US as RFK Jr targets 7-OH: What is it and how can it impact your health?
Synopsis The FDA is considering scheduling 7-OH, a kratom byproduct, as an illicit drug due to addiction risks. Kratom, sold as a supplement for pain relief and energy, is available nationwide in various forms. Concerns are rising about its addictive potential, likened to opioids, especially with products containing concentrated 7-OH. An uptick in 7-OH-related medical events has led the Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) to crack down on sellers of these products. Kratom has gained massive popularity in the US following a viral TikTok video and Health and Human Services (HHS) Secretary Robert F. Kennedy Jr's recent press conference. Kratom is in the spotlight in the United States. Kratom is a tropical tree (Mitragyna speciosa) that is native to Southeast Asia and products prepared from kratom leaves are available in the U.S. through sales on the Internet and at brick-and-mortar stores, according to the Food and Drug Administration (FDA)Kratom is often used to self-treat conditions such as pain, coughing, diarrhea, anxiety and depression, opioid use disorder, and opioid withdrawal. Last week, FDA Commissioner Marty Makary announced that the Trump administration has recommended that a compound called 7-OH be scheduled as an illicit drug. The compound is a by-product of the Kratom plant whose ground leaves are sold as a dietary supplement to boost energy or provide pain relief. According to USA Today, products containing the plant ingredient kratom are sold across the country at gas stations, liquor stores and smoke shops. They come in drinks, capsules and powders with medical experts having warned that it can be highly addictive, producing effects similar to those of opioids and opiates. They are available in three forms: beverages, capsules, and powder and some are even available in brightly colored packaging. ALSO READ: Blue whales' mysterious silence leave scientists worried as it sends a dire warning to humanity Kratom has gained massive popularity in the US following a viral TikTok video and Health and Human Services (HHS) Secretary Robert F. Kennedy Jr's recent press conference. Dr. Timothy Fong, a UCLA addiction psychiatrist, told USA Today the ability of companies to put large amounts of kratom into otherwise innocuous-looking products has made it more susceptible to abuse. During a July 29 press conference, Food and Drug Administration commissioner Martin Makary announced the organization's intention to crackdown on products containing 7-OH; however, Makary also made clear during that press conference that the organization's focus is on 7-OH, not kratom overall. ALSO READ: Uber shocks Wall Street with massive $20 billion buyback: What it means and why companies do it FDA officials said 7-OH has a 'high risk of addiction' and abuse because of its ability to bind to opioid receptors in the brain. The compound is found in trace amounts in the kratom plant, and the FDA's move is aimed at products with concentrated levels of 7-OH. 'We have a history in public health of being asleep at the wheel,' Makary said. 'Public health is supposed to prevent disasters, not just clean them up after they've killed thousands and thousands of people.' 'Today, we're taking action on 7-OH as a critical step in the fight against opioid addiction,' RKF Jr said during a July 29 press conference. 'We will protect the health of our nation's youth as we advance our mission to Make America Healthy Again.'"I spent 14 years a heroin addict, and I've been 43 years in recovery," Kennedy said during the press conference. "I've had iron willpower for most of my life. ... This compulsion was absolutely impervious to my will, and part of the problem was just the availability."Makary alongside with RFK Jr announced their plan to initiate the process to have 7-OH scheduled as an illicit substance. That will happen if the Drug Enforcement Administration approves the FDA's sanction after review. ALSO READ: ESPN adds WWE's WrestleMania, Royal Rumble as streaming service sets August 21 launch. Check details Medical experts told USA TODAY that while kratom and 7-OH remain largely understudied, all kratom products pose a risk of addiction—not just those marketed with 7-OH. Some individuals said their dependency was solely on kratom-based products and that they had never used ones containing synthetic 7-OH. For others, kratom use served as a gateway to trying products with synthetic there are multiple kratom products on the market, but one particular drink has gone viral in recent weeks. On July 25, a TikToker under the name @yourbestimisha posted a video that now has over 19 million views, in which he described how a teenage boy tried stealing his wallet outside a gas station after he refused to go inside to buy the boy a Feel Free tonic containing kratom. A representative for Botanic Tonics, the company behind Feel Free, told USA TODAY its Feel Free Classic tonic contains only natural leaf kratom, with nearly undetectable levels of 7-OH.
Hindustan Times
12 hours ago
- Hindustan Times
Kratom rise sparks concerns over addiction amid RFK Jr's 7-OH crackdown; What is it and how it impacts your health
Kratom has gained popularity following a viral TikTok video and Health and Human Services (HHS) Secretary Robert F. Kennedy Jr's recent press conference. Kratom-containing products are sold all over the country in gas stations, alcohol stores, and smoke shops.(X@LuLFo9) Kratom-containing products are sold all over the country in gas stations, alcohol stores, and smoke shops. They are available in three forms: beverages, capsules, and powder and some are even available in brightly colored packaging. Medical specialists believe kratom is highly addictive and gives similar effects like opioids and opiates. USA TODAY recently surveyed over 20 people who were severely addicted to kratom, leading to terrible outcomes. Meanwhile, several people on social raised an alarm over the usage of Kratom, claiming its adverse affects on health. 'WARNING: 'Feel Free' isn't as safe as it sounds. This kratom-based drink is being sold as a natural energy boost — but it's linked to addiction, liver damage, and even death,' one person claimed on X expressing worries over Kratom use. "Stay AWAY from the "herbal" drink, Feel Free. Unless you want to walk right into ADDICTION! It is suppose to be sold to people who are 21 and you can easily get it at any gas station. It has an UNREGULATED ingredient called kratom," another said. What we know about RFK Jr.'s crackdown on 7-OH In his briefing, RFK Jr. discussed the steps the government will take in reaction to a 'dangerous' synthetic opioid produced from kratom. 'Today, we're taking action on 7-OH as a critical step in the fight against opioid addiction,' he said during a July 29 press conference. 'We will protect the health of our nation's youth as we advance our mission to Make America Healthy Again.' The FDA issued this proposal after conducting an extensive medical and scientific investigation, and it is one of numerous measures to deal with the agency's concerns about the growing accessibility and usage of 7-OH opioid medications. There are no FDA-approved 7-OH medications, 7-OH is not allowed in dietary supplements, and 7-OH cannot be added to ordinary meals. Also Read: Who is Peter Alt? Long Island fire chief fired for hurling abuses, shouting at 10-year-old girl in crisis What is Kratom and how it is different from 7-OH Kratom is a plant product that is found in Southeast Asia. It's frequently sold as a herbal supplement that improves relaxation and increases vitality. Kratom refers to the complete plant substance, whereas 7-OH, which is abbreviated for 7-Hydroxymitragynine, is a chemical byproduct of kratom. Some products are manufactured from the entire kratom plant, while others are prepared with high amounts of 7-OH. Products advertised with 7-OH are often stronger and have recently come under scrutiny from the FDA. Kratom, according to Dr. Lief Fenno, chair of the American Psychiatric Association Council on Addiction Psychiatry, has managed to get away from scrutiny because it doesn't connect with brain receptors like heroin and morphine.
